Experimental Treatments for Pulmonary Fibrosis

AD-114 is based on shark antibodies, the proteins that help keep sharks healthy. Antibodies are proteins the immune system uses to kill invaders. It has many advantages over traditional monoclonal antibodies because of its unique structure. AD-114 has been improved and modified and has been renamed AD-214. A Phase 1 trial in healthy volunteers is now recruiting.

GB0139 is an experimental medication for IPF that is administered with an inhaler. It contains a small molecule that inhibits a protein called galectin-3, which promotes tissue scarring and inflammation. By blocking galectin-3, GB0139 may be able to reduce lung fibrosis. A Phase 2b trial is now enrolling IPF patients.

LTI-03 is an inhaled therapy that’s being developed by Rein Therapeutics as a possible treatment to preserve lung function and slow disease progression in idiopathic pulmonary fibrosis. It’s designed to be administered using a dry powder inhaler.

Tipelukast is primarily an anti-fibrotic and anti-inflammatory therapy that was initially designed to treat interstitial cystitis and asthma. A Phase 2 trial is ongoing in adults with moderate to severe IPF.